A b s t r a c t
Caveolins are the major structural proteins of caveolae, the vesicular invaginations of the plasma membrane. 1, 2 The caveolin (Cav) family includes Cav-1, Cav-2, and Cav-3. Previous studies have revealed that Cav-1 and Cav-2 are present primarily in vascular endothelial cells, adipocytes, smooth muscle cells, and fibroblasts, 3 while Cav-3 is expressed specifically in skeletal and cardiac muscle. 4 The genes encoding human Cav-1 and Cav-2 have been localized to chromosome 7q31.1. 5 Cav-1 and Cav-2 form a stable hetero-oligomeric complex, and the intracellular transport of Cav-2 requires the presence of Cav-1. 6 In addition to transporting cholesterol and glycosphingolipids, caveolins interact with a range of proteins. Structural studies have demonstrated that caveolin family members contain a common domain, termed caveolin-scaffolding domain, that functions in the sequestration and organization of signaling molecules, 7 including G-protein α-subunits, 8 Ha-ras, 9, 10 Src-family tyrosine kinases, 9 endothelial nitric oxide synthase, [11] [12] [13] [14] epidermal growth factor (EGF)-receptor, 15, 16 and c-neu. 17 In vitro and in vivo studies have revealed that Cav-1 exerts negative regulatory effects on the molecules it interacts with, resulting in inhibition of cell growth or transformation. 3, 18, 19 Based on these findings, much effort has been devoted to study the roles of Cav-1 in neoplasms. Reduced expression of Cav-1 has been shown to be associated with ovarian carcinoma 20 and many sarcomas, 21 while hypermethylation of its promoter region has been detected in prostate carcinoma. 22 On the other hand, expression of Cav-1 has been found to be elevated in cancers of the prostate, breast, esophagus, and colon. [23] [24] [25] The role of Cav-1 in human neoplasms remains uncertain.
Urothelial carcinoma (UC) is a common neoplasm arising from the urothelium lining the urinary bladder, the ureters, and the renal pelvis. UC can be divided, according to its growth patterns and behaviors, into 3 types: superficial papillary UC, flat carcinoma in situ (CIS), and nonpapillary UC. Superficial papillary UC and flat CIS are early, noninvasive, or superficially invasive lesions, while the latter is aggressive with deep invasion and a high mortality rate. 26, 27 Cytogenetic and molecular genetic studies have disclosed multiple genetic alterations associated with UC, including loss of heterozygosity in several chromosomal arms, mutation inactivation and homozygous deletion of several tumor suppressor genes, and amplification of some oncogenes. 28 Overexpression of oncogene products such as EGF receptor, erb-B2, mdm-2, and p53 is detected frequently in UC by immunohistochemical analysis. 29, 30 On the other hand, the expression of Rb, a tumor suppressor gene, is found to be reduced. 31 Although low-grade noninvasive papillary UC (Ta) shares many genetic changes with high-grade invasive carcinoma, some distinctions exist. Loss of heterozygosity of chromosome 9 frequently occurs in the former, but is a much more rare event in CIS and high-grade invasive UC. In contrast, mutation of p53 is much more common in CIS and high-grade invasive UC than in Ta. 32, 33 In the present study, we analyzed the expression of Cav-1 and Cav-2 to assess their possible roles in the tumorigenesis of UC.
Materials and Methods

Case Selection
All patients were from the Montefiore Medical Center, Bronx, NY. Patients with a history of UC and resection were identified through a SNOMED search. Ninety-four specimens from 82 patients, including 35 cystectomies and 59 transurethral resections, were selected for study. These specimens spanned a period from 1993 to 1999. Fifty-eight patients were men and 24 were women. Their ages ranged from 39 to 97 years. H&E-stained slides were reviewed, and tumors were graded according to the World Health Organization grading criteria 34 and staged using the American Joint Committee on Cancer staging system. 35 Tissue blocks containing representative tumor tissue were selected from the pathology files of the Montefiore Medical Center.
Immunohistochemical Studies
Five-µm-thick sections from formalin-fixed, paraffinembedded blocks were mounted onto glass slides. The tissue sections then were deparaffinized, rehydrated, and quenched with hydrogen peroxide. For antigen retrieval, slides were incubated with DAKO Epitope Buffer (DAKO, Carpinteria, CA) in a steam bath at 95°C for 45 minutes. After equilibration in phosphate-buffered saline for 15 minutes, the slides were placed in an autostainer (DAKO) and stained with monoclonal antibodies to Cav-1 and Cav-2 (1:200 and 1:100 dilutions in phosphate-buffered saline containing 1% bovine serum albumin, respectively; Transduction Laboratories, Lexington, KY). Immunoreactivity was detected using DAKO EnVision methods according to manufacturer-recommended procedures. For negative controls, slides were treated with the same procedures, including antigen retrieval, except for the replacement of primary antibodies with a negative diluent (Zymed, San Francisco, CA).
The immunoreactivity was scored according to the following criteria: 0, 0% to 5% of tumor cells stained; 1, 6% to 20% of tumor cells stained; 2, 21% to 50% of tumor cells stained; and 3, more than 50% of tumor cells stained. A score of 0 was considered as negative, while a score of 1, 2, or 3 was positive.
Statistical Analysis
The Cochran-Armitage test was used to examine the trend in the proportion of cases in which Cav-1 and Cav-2 were expressed, for both tumor grade and stage. This test permits stage and grade to be analyzed as ordinal covariates and tests for trends in the proportion of Cav expression (any positive staining) across levels. All P values provided were computed using exact methods.
A logistic regression model was fit to assess the multivariable relationship between tumor grade and stage with respect to Cav expression.
Results
With antigen retrieval, the immunohistochemical staining was satisfactory for interpretation in almost all cases studied. Smooth muscle, endothelial cells, and adipocytes served as internal controls. Diffuse cytoplasmic staining was observed in most positive tumor cells, although a membranous pattern also was present in some cases ❚Image 1❚. The results are summarized in ❚Table 1❚. Thirty-five (37%) of 94 cases and 45 (51%) of 89 cases were positive for Cav-1 and Cav-2, respectively. All Cav-1-positive cases also were positive for Cav-2, and the staining for Cav-2 generally was stronger than for Cav-1. In most Cav-1-positive cases, the staining was patchy (with a score of 1 or 2). We also observed that in some cases, the tumor cells in the invading front stained more strongly ❚Image 2❚.
Correlation of Cav-1 and Cav-2 reactivity with tumor grade and stage is summarized in ❚Table 2❚. There was a positive correlation between tumor grade and the expression of Cav-1 (P < .001) and Cav-2 (P < .001). None of the grade 1 (0/6) and grade 2 (0/25) tumors were positive for Cav-1. In contrast, 35 (56%) of 63 cases of grade 3 tumors were positive. A similar ratio was obtained for Cav-2. Although the expression of both Cav-1 and Cav-2 increased with higher tumor stage, there was no correlation after correction for tumor grade.
In 22 cases, benign urothelium was present and showed complete negative reactivity with Cav-1 and Cav-2 ❚Table 3❚ and ❚Image 3A❚. Squamous metaplasia of the nonneoplastic urothelium was noted in 7 cases, and 2 of these cases showed focal reactivity with Cav-1 in the basal layers ❚Image 3B❚. In 10 cases, flat CIS coexisted with invasive UC. While the invasive component showed positive staining for both Cav-1 and Cav-2 in 5 of the 10 cases, the in situ component was negative in all of them.
Focal or extensive squamous differentiation was present in 15 high-grade (grade 3) UC cases. In addition, 2 cases were pure squamous cell carcinoma. Fourteen (82%) of these 17 cases were positive for Cav-1 ❚Table 4❚. Furthermore, in cases in which both transitional and squamous components were present, staining often was stronger in the latter ❚Image 4❚. In contrast, only 20 (29%) of 70 cases without squamous differentiation were positive for Cav-1. When only grade 3 tumors were considered, 20 (43%) of 46 of the latter tumors were positive, which was significantly lower than in tumors with squamous differentiation (P < .001). Of 6 cases with glandular differentiation, 1 was positive for Cav-1. One small cell carcinoma was negative.
Discussion
The genes for Cav-1 and Cav-2 are located at human chromosome 7q31.1, 5 a region frequently deleted in a variety of human cancers, including prostate, breast, ovarian, and oral cancers. [36] [37] [38] [39] Several in vivo studies have suggested that Cav-1 may act as a suppressor of cell transformation and tumorigenesis. Cav-1 messenger RNA and protein levels were down-regulated during cell transformation of culture NIH3T3 cells, in breast cancer of transgenic mice models, and in cell lines derived from human breast cancer. 17, 40 Galbiati et al 41 demonstrated that targeted down-regulation of Cav-1 expression promoted anchorage-independent cell growth, drove tumorigenesis in nude mice, and hyperactivated the p42/44 mitogen-activated protein kinase cascade. Engelman et al 17 found that mutational activation of c-neu, an oncogene, down-regulated Cav-1 protein expression and that Cav-1 was reduced dramatically in mammary tumors derived from cneu-expressing transgenic mice while recombinant overexpression of Cav-1 blocked neu-mediated signal transduction. These results imply a reciprocal relationship between Cav-1 and neu. Similar results were obtained by Lee et al, 42 who found that Cav-1 expression was down-regulated in human breast cancer cells and reexpression of Cav-1 inhibited tumor cell growth. Fiucci et al 43 also found that expression of Cav-1 inhibited anchorage-independent growth, anoikis, and invasiveness in MCF-7 human breast cancer cells. 0  24  2  2  0  0  25  2  2  0  0  26  2  3  0  0  27  3  1  0  0  28  3  1  0  0  29  3  1  0  0  30  3  1  0  0  31  3  2  0  0  32  3  2  0  0  33  3  2  0  0  34  3  2  0  0  35  3  2  0  0  36  3  2  0  0  37  3  2  0  0  38  3  3  0  0  39  3  3  0  0  40  3  3  0  0  41  3  3  0  0  42  3  3  0  0  43  3  3  0  0  44  3  4  0  0  45  3  4  0  0 48  2  a  0  1  49  2  1  0  1  50  3  2  0  1  51  3  2  0  1  52  3  2  0  1  53  3  3  0  1  54  3  2  0  2  55  3  3  0  2  56  3  ND  0  2  57  2  1  0  ND  58  2  1  0  ND  59  3  3  0  ND  60  3  2  1  1  61  3  2  1  1  62  3  3  1  1  63  3  3  1  1  64  3  3  1  1  65  3  4  1  1  66  3  1  1  2  67  3  2  1  2  68  3  2  1  2  69  3  2  1  2  70  3  2  1  2  71  3  2  1  2  72  3  2  1  2  73  3  3  1  2  74  3  3  1  2  75  3  ND  1  2  76  3  1  1  3  77  3  3  1  3  78  3  3  1  3  79  3  2  2  2  80  3  2  2  2  81  3  3  2  2  82  3  1  2  3  83  3  2  2  3  84  3  2  2  3  85  3  2  2  3  86  3  2  2  3  87  3  3  2  3  88  3  3  2  3  89  3  1  3  3  90  3  2  3  3  91  3  2  3  3  92  3  3  3  3  93  3  3  3  3  94  3  3 20 Wiechen et al 21 have shown that Cav-1 was down-regulated in several types of sarcomas. It also has been demonstrated by Cui et al 22 that in prostate carcinoma, the promoter region of Cav-1 was hypermethylated. Conversely, elevated expression of Cav-1 has been found in carcinoma of the prostate, breast, esophagus, colon, and thyroid. [23] [24] [25] 44 Yang et al 23 found that expression of Cav-1 was increased in cases of in situ and invasive ductal carcinoma of the breast. They also demonstrated elevated expression of Cav-1 in primary and metastatic prostatic carcinoma, suggesting an association of Cav-1 expression with tumor progression. 23, 45 Fine et al 25 found that Cav-1 was expressed in colonic adenocarcinoma but not in normal mucosa or adenoma. In esophageal squamous cell carcinoma, Kato et al 24 showed a correlation of overexpression of Cav-1 with tumor stage and lymph node metastasis. In addition, elevated expression of Cav-1 has been found to be associated with drug-resistant cancer cell lines, such as paclitaxel-resistant human lung cancer cell lines 46 and androgen-insensitive mouse prostate cancer cells. 47 These findings have led some investigators to hypothesize that Cav-1 may have a role in various stages of carcinogenesis.
The present study has demonstrated that Cav-1 and Cav-2 are not detectable in benign urothelium but are expressed in some urothelial carcinomas. Expression is correlated with tumor grade. In low-grade carcinomas, Cav-1 and Cav-2 were not detectable, while in high-grade tumors, there was elevated expression, indicating that the increased expression of Cav-1 is a late event. These findings are similar to those of Rajjayabun et al, 48 who studied 89 cases of UC immunohistochemically using an anti-Cav-1 polyclonal antibody and found a statistically significant association between Cav-1 immunoreactivity and tumor grade. In addition, we demonstrated that there was an increase in staining in both benign squamous metaplasia and UC with squamous differentiation. This increase was statistically significant even after correction for tumor grade (ie, only the grade 3 tumors were considered). High-grade UC often show foci of squamous, glandular, and small cell differentiation. 26 Squamous differentiation, defined by the presence of intercellular bridges or keratinization, occurs up to 20% of UC cases. 49, 50 Although the clinical significance of squamous differentiation remains uncertain, some studies have shown that it was associated with unfavorable prognosis 51 and was predictive of a poor response to radiation therapy 50 and systemic chemotherapy. 52 Although it may represent an epiphenomenon, the positive association of Cav-1 expression and squamous differentiation in UC suggests that Cav-1 may have a role in squamous differentiation. Further studies are necessary to confirm this role. Our findings that the expression of Cav-2 was similar to that of Cav-1 in both nonneoplastic and neoplastic urothelium further support the concept that Cav-1 and Cav-2 are functionally closely related.
The results of our present study and of those of others [23] [24] [25] 44, 48 that the expression of Cav-1 is elevated in certain types of human cancer and cancer cell lines seem to conflict with the negative regulatory effect of Cav-1. However, the mechanisms and significance of increased Cav-1 expression in variable types of tumor are not clear. One possibility is that Cav-1 and Cav-2 indeed may have a role in the tumorigenesis. Although Cav-1 exerts predominantly negative regulatory effects through its scaffolding domain, it also augments the positive signaling function of insulin receptor. 19 Furthermore, it has been found that Cav-1 is a substrate of c-Src kinase, which phosphorylates Cav-1 at tyrosine-14. 53 The phosphorylated Cav-1 then binds to Grb7 (growth factor receptor-binding protein 7). The cooperative effect of c-Src, Cav-1, and Grb-7 results in anchorage-independent growth and EGF-stimulated cell migration. 48 Therefore, the divergent effects of Cav-1 may be mediated by different regions of the molecule and may depend on the levels of other molecules that are coexpressed with Cav-1.
It has been shown that interactions with Cav-scaffolding domain confer the transformation suppressor activity, while tyrosine-14 phosphorylation of Cav-1 results in a growth stimulating effect. 53 Alternatively, Cav-1 may have a dominant negative effect. Hayashi et al 54 found that a point mutation at codon 132 of the Cav-1 gene (P132L) was present in 16% of 92 cases of invasive scirrhous carcinoma of the breast and hypothesized that functional activation of Cav-1 may have a role in the progression of breast carcinoma. They also demonstrated that expression of the same mutant Cav-1 in the NIH3T3 cell line induced transformation and promoted the ability for invasion. These findings are further supported by those of Lee et al 55 that P132L mutation led to the formation of misfolded Cav-1 oligomers that were retained within the Golgi complex and were not targeted to caveolae. Furthermore, when the mutant Cav-1 (P132L) was cotransfected with wild-type Cav-1 into cultured cells, it behaved in a dominant-negative manner, causing the mislocalization and intracellular retention of the wild-type Cav-1. Therefore, it is possible that the increase in cellular Cav-1 protein in various tumor types is due to mutations in its gene that may exert a dominant negative effect. In this regard, it is noteworthy that the elevated expression of Cav-1 and Cav-2 in UC of the bladder in the present study was present predominantly in the cytoplasm, an abnormal intracellular location that may correspond to the mislocalization of mutant Cav-1 (P132L). Studies on the Cav-1 gene (amplification, deletion, and mutation) with correlation with protein levels and their intracellular localization in human neoplasms should further help to determine the roles and mechanisms of action of Cav-1 and Cav-2.
Our immunohistochemical study has shown that Cav-1 and Cav-2 were detected in some UC cases, but not in nonneoplastic urothelium. The elevated expression of Cav-1 and Cav-2 in UC correlated with tumor grade and squamous differentiation, suggesting that they be studied further for a possible role in tumor progression and squamous differentiation.
